Evidence map›Paper›PMID 24244896›Full record

ArticleOncoimmunology2013

Combining cellular and gene therapy approaches for treatment of intracranial tumors.

Michelle J Hickey, Noriyuki Kasahara, Barbara M Mueller, Carol A Kruse

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Michelle J HickeyDepartment of Neurosurgery; University of California Los Angeles; Los Angeles, CA USA.
Noriyuki Kasahara
Barbara M Mueller
Carol A Kruse
University of California, Los Angeles · USUniversity of California, San Diego · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent GliomasR01CA125244 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIAU, LINDA M · 2010 to 2014
$2.4M
Cellular Transduction with Replication-Competent Retrovirus VectorsR01CA121258 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KASAHARA, NORIYUKI · 2007 to 2011
$2.3M
Optimizing Induction Conditions for Immunotherapeutic CTLR01CA154256 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PRINS, ROBERT M · 2010 to 2014
$1.9M
NCATS NIH HHS UL1 TR000124NCI NIH HHS R01 CA121258NCI NIH HHS R01 CA125244NCI NIH HHS R01 CA154256
6 · The paper itself

Abstract

New treatments are needed for brain metastasis, which is associated with high morbidity and mortality. Two novel cellular and gene therapy modalities were evaluated in xenograft models for human breast cancer. The individual and especially the combined treatments with alloreactive cytotoxic T lymphocytes and replicating retroviral vectors coding for prodrug activating enzymes followed later with nontoxic prodrug demonstrated efficacy without off-target effects.

Indexed as

alloCTLbrain cancerbreast cancergene therapyimmunotherapymetastasisretrovirus

Identifiers

PMID24244896
PMCPMC3825732
OpenAlexW2038832149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.